Optos AMD Solutions

Ultra-widefield imaging has been shown to contribute to the benefits in the diagnosis and management of AMD.

Using ultra-widefield optomap colour and autofluorescence retinal images as part of your comprehensive ocular health. In partnership with Valeda, Optos has created a new program aimed at preventing vision loss due to Dry AMD. Studies have shown that AMD may be more than a “macular” condition but one that involves the entire retina.

Using new technology to find, test, and treat dry AMD this program offers patients with Dry AMD the hope of years of good vision.

First approved treatment for Dry Age-Related Macular Degeneration using photobiomodulation. Valeda is a platform with the potential to successfully treat a number of degenerative ocular diseases. The Valeda Light Delivery System is the first and only approved treatment for dry AMD using photobiomodulation (PBM), creating a brighter horizon for patients by developing treatment solutions to improve visual function, stop or slow the progression of debilitating eye diseases and prevent vision loss and blindness.

Valeda was designed for ease of use in the doctor’s surgery

Under the doctor’s supervision, trained staff are able to administer the Valeda treatment.

• Excellent safety profile
• Preserves future treatment options

Treatments are delivered in a series of 9 sessions per eye over a three-week period. Each treatment session lasts less than 5 minutes per eye.

Learn More